Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group

Galldiks, Norbert; Albert, Nathalie L; Soffietti, Riccardo; Langen, Karl-Josef; Weller, Michael; Villanueva-Meyer, Javier E; Tonn, Joerg C; Law, Ian; Kim, Michelle M; Wen, Patrick Y

doi:10.1093/neuonc/noac131

Journal Article

FZJ-2022-03213

Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group

Galldiks, N. (Corresponding author)FZJ* ; Langen, K.-J.FZJ* ; Albert, N. L. ; Law, I. ; Kim, M. M. ; Villanueva-Meyer, J. E. ; Soffietti, R. ; Wen, P. Y. ; Weller, M. ; Tonn, J. C.

2022
Oxford Univ. Press Oxford

Neuro-Oncology 24(11), 1815–1826 (2022) [10.1093/neuonc/noac131]

This record in other databases:

Please use a persistent id in citations: http://hdl.handle.net/2128/33045 doi:10.1093/neuonc/noac131

Abstract: Many studies in patients with brain tumors evaluating innovative PET tracers have been published in recent years, and the initial results are promising. Here, the Response Assessment in Neuro-Oncology (RANO) PET working group provides an overview of the literature on novel investigational PET tracers for brain tumor patients. Furthermore, newer indications of more established PET tracers for the evaluation of glucose metabolism, amino acid transport, hypoxia, cell proliferation, and others are also discussed. Based on the preliminary findings, these novel investigational PET tracers should be further evaluated considering their promising potential. In particular, novel PET probes for imaging of translocator protein and somatostatin receptor overexpression as well as for immune system reactions appear to be of additional clinical value for tumor delineation and therapy monitoring. Progress in developing these radiotracers may contribute to improving brain tumor diagnostics and advancing clinical translational research.

Classification: